Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free ARWR Stock Alerts

Arrowhead Pharmaceuticals (ARWR) Earnings Date, Estimates & Call Transcripts

Arrowhead Pharmaceuticals logo
$85.59 -1.66 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$85.59 0.00 (0.00%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Arrowhead Pharmaceuticals Earnings Summary

Arrowhead Pharmaceuticals posted Q3 2026 earnings on August 4, 2026, reporting an EPS of -$1.36, which missed analysts' consensus estimates of -$1.23 by $0.13. Quarterly revenue rose 171.0% year-over-year to $75.25 million, above analysts' expectations of $44.17 million. With a trailing EPS of -$2.25, Arrowhead Pharmaceuticals' earnings are expected to decrease next year, from ($3.51) to ($4.77) per share.

Latest Q3
Earnings Date
Aug. 4Estimated
Consensus EPS
(Aug. 4)
-$1.23
Actual EPS
(Aug. 4)
-$1.36 Missed By -$0.13
Actual Revenue
(Aug. 4)
$75.25M

Q3 2026 Earnings Resources

Powered by Quartr
Get Arrowhead Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arrowhead Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

ARWR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ARWR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arrowhead Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261$1.63$1.63$1.63
Q2 20262-$1.29-$0.98-$1.14
Q3 20262-$1.49-$1.03-$1.26
Q4 20262-$2.74-$1.35-$2.05
FY 2026 7 -$3.89 -$1.73 -$2.81
Q1 20271-$1.42-$1.42-$1.42
Q2 20271-$1.64-$1.64-$1.64
Q3 20271-$1.65-$1.65-$1.65
Q4 20271$0.08$0.08$0.08

Arrowhead Pharmaceuticals Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/4/2026Q3 2026-$1.23-$1.36 -$0.13-$1.36$44.17M$75.25M
5/7/2026Q2 2026-$1.0950-$0.93+$0.1650-$0.93$73.84M$73.74M
2/5/2026Q1 2026$0.60$0.22 -$0.38$0.22$225.66M$264.03M
8/7/2025Q3 2025-$0.94-$1.26 -$0.32-$1.26$29.01M$27.77M
5/12/2025Q2 2025-$0.06$2.75+$2.81$2.75$116.27M$542.71M
2/10/2025Q1 2025-$0.42-$1.39 -$0.97-$1.39$19.05M-

Arrowhead Pharmaceuticals Earnings - Frequently Asked Questions

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earning data on Tuesday, August 4, 2026. Learn more on ARWR's earnings history.

In the previous quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) missed the analysts' consensus estimate of ($1.23) by $0.13 with a reported earnings per share (EPS) of ($1.36). Learn more on analysts' earnings estimate vs. ARWR's actual earnings.

The conference call for Arrowhead Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Arrowhead Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Arrowhead Pharmaceuticals' earnings report can be found in their filing with the SEC.
View SEC filing

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded annual revenue of $669.50 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$1.63 million. ARWR has generated -$2.25 earnings per share over the last four quarters.

Arrowhead Pharmaceuticals' earnings are expected to decrease from ($3.51) per share to ($4.77) per share in the next year.

Related Companies
Earnings Tools

Earnings data for NASDAQ:ARWR is sourced from Fiscal.ai, with the most recent quarter reported on 8/4/2026. New results are added as companies report their earnings.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel